NCT00282386

A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,586 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside (the lining) of the large intestine, also known as the colon) in patients with a history of colorectal adenomas.

Conditions

• Colorectal Adenoma

Interventions

Type	Name	Description
DRUG	MK0966; Rofecoxib / Duration of Treatment: 156 weeks
DRUG	Placebo/ Duration of Treatment: 156 weeks

Timeline

• Start date: 1999-12-23
• Primary completion: 2004-09-01
• Completion: 2004-09-01
• First posted: 2006-01-26
• Last updated: 2017-05-09